Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study

European urology oncology - Tập 6 - Trang 437-446 - 2023
Viktor Grünwald1, Thomas Powles2, Evgeny Kopyltsov3, Vadim Kozlov4, Teresa Alonso-Gordoa5, Masatoshi Eto6, Thomas Hutson7, Robert Motzer8, Eric Winquist9, Pablo Maroto10, Bhumsuk Keam11, Giuseppe Procopio12, Shirley Wong13, Bohuslav Melichar14, Frederic Rolland15, Mototsugu Oya16, Karla Rodriguez-Lopez17, Kenichi Saito18, Jodi McKenzie18, Camillo Porta19
1Interdisciplinary Genitourinary Oncology, Clinic for Urology, Clinic for Medical Oncology, University Hospital Essen, Essen, Germany
2The Royal Free NHS Trust, London, England, UK
3State Institution of Healthcare “Regional Clinical Oncology Dispensary”, Omsk, Russia
4State Budgetary Health Care Institution “Novosibirsk Regional Clinical Oncology Dispensary”, Novosibirsk, Russia
5Hospital Universitario Ramón y Cajal, Madrid, Spain
6Kyushu University, Fukuoka, Japan
7Texas Oncology, Dallas, TX, USA
8Memorial Sloan-Kettering Cancer Center, New York, NY, USA
9University of Western Ontario London, Ontario, Canada
10Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
11Seoul National University Hospital, Seoul, Republic of Korea
12Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy
13Western Health, VIC, Australia
14Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
15Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes, Saint-Herblain, France
16Keio University School of Medicine, Tokyo, Japan
17Merck & Co., Inc., Rahway, NJ, USA
18Eisai Inc., Nutley, NJ, USA.
19University of Bari ‘A. Moro’, Bari, Italy

Tài liệu tham khảo